News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
Wednesday, January 08, 2025Hummingbird Bioscience a precision biotherapeutics company discovering and developing transformative biologics for hardtotreat diseases today announced it has granted Immunome Inc a biotechnology company focused on developing firstinclass and bestinc...
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
Tuesday, January 07, 2025Clearmind Medicine Inc a clinicalstage biotech company focused on discovery and development of novel psychedelicderived therapeutics to solve major undertreated health problems today announced the publication of a European patent application with the...
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Tuesday, January 07, 2025Fortress Biotech Inc and its majorityowned subsidiary Cyprium Therapeutics Inc today announced the acceptance for review of the New Drug Application NDA by the US Food and Drug Administration FDA for CUTX Copper Histidinate for the treatment
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
Friday, January 03, 2025ACELYRIN INC a latestage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology today announced it will host a virtual investor event on Monday January at PM ET to provide updated
Evaxion announces plan to implement ADS ratio change
Tuesday, December 31, 2024Evaxion Biotech AS a clinicalstage TechBio company specializing in developing AIImmunology powered vaccines today announced that it plans to change the ratio of its American Depositary Shares ADSs to its ordinary shares DKK nominal value
Orion and Marinus terminate agreement for ganaxolone in Europe
Monday, December 30, 2024Orion Corporation and Marinus Pharmaceuticals Inc have decided to mutually terminate their European wide marketing and distribution agreement for ganaxolone Marinus regains ganaxolones commercial rights in Europe where the compound is approved for th...
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
Friday, December 27, 2024Viracta Therapeutics Inc a clinicalstage precision oncology company focused on the treatment and prevention of virusassociated cancers that impact patients worldwide today announced that its Board of Directors has initiated a process to explore a bro...
FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes
Monday, December 23, 2024The US Food and Drug Administration approved the first generic referencing Victoza liraglutide injection milligram milliliter a glucagonlike peptide GLP receptor agonist indicated to improve glycemic control in adults and pediatric patients aged ye...
Epitopea and Genevant Sciences Announce Collaboration Agreement
Friday, December 20, 2024Epitopea a transatlantic cancer immunotherapeutics company developing accessible offtheshelf RNAbased immunotherapies and Genevant Sciences a leading nucleic acid delivery company with worldclass platforms and a robust and expansive lipid nanoparticl...
Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101
Friday, December 20, 2024Vittoria Biotherapeutics Inc a clinicalstage immunotherapy company specializing in the development of innovative cell therapies for hardtotreat diseases today announced that in November the first patient was dosed in its Phase clinical trial of VIPE...
